Log in

NASDAQ:SCYXSCYNEXIS Stock Price, Forecast & News

$0.77
-0.02 (-2.52 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.77
Now: $0.77
$0.79
50-Day Range
$0.78
MA: $0.87
$1.02
52-Week Range
$0.50
Now: $0.77
$1.44
Volume552,081 shs
Average Volume1.07 million shs
Market Capitalization$76.35 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase 2 clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Read More
SCYNEXIS logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SCYX
CUSIPN/A
Phone201-884-5485

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$120,000.00
Book Value$0.07 per share

Profitability

Net Income$-53,710,000.00

Miscellaneous

Employees27
Market Cap$76.35 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive SCYX News and Ratings via Email

Sign-up to receive the latest news and ratings for SCYX and its competitors with MarketBeat's FREE daily newsletter.

SCYNEXIS (NASDAQ:SCYX) Frequently Asked Questions

How has SCYNEXIS's stock been impacted by COVID-19 (Coronavirus)?

SCYNEXIS's stock was trading at $0.7802 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SCYX shares have decreased by 1.0% and is now trading at $0.7727. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SCYNEXIS?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SCYNEXIS in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SCYNEXIS.

When is SCYNEXIS's next earnings date?

SCYNEXIS is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for SCYNEXIS.

How were SCYNEXIS's earnings last quarter?

SCYNEXIS Inc (NASDAQ:SCYX) released its earnings results on Monday, May, 11th. The company reported ($0.07) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.08. View SCYNEXIS's earnings history.

What price target have analysts set for SCYX?

6 equities research analysts have issued 12 month price targets for SCYNEXIS's shares. Their forecasts range from $3.50 to $6.00. On average, they anticipate SCYNEXIS's stock price to reach $4.60 in the next year. This suggests a possible upside of 495.3% from the stock's current price. View analysts' price targets for SCYNEXIS.

Has SCYNEXIS been receiving favorable news coverage?

Media stories about SCYX stock have been trending extremely negative recently, InfoTrie reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. SCYNEXIS earned a coverage optimism score of -4.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutSCYNEXIS.

Who are some of SCYNEXIS's key competitors?

What other stocks do shareholders of SCYNEXIS own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SCYNEXIS investors own include Cerus (CERS), Novavax (NVAX), Inovio Pharmaceuticals (INO), Micron Technology (MU), Matinas BioPharma (MTNB), Verastem (VSTM), Outlook Therapeutics (OTLK), Viking Therapeutics (VKTX), Trevena (TRVN) and T2 Biosystems (TTOO).

Who are SCYNEXIS's key executives?

SCYNEXIS's management team includes the following people:
  • Dr. Marco Taglietti, CEO, Pres & Director (Age 60, Pay $937.35k)
  • Mr. Eric Francois, Chief Financial Officer (Age 45, Pay $604.91k)
  • Mr. David Gonzalez Angulo, Chief Medical Officer (Age 55, Pay $676.13k)
  • Mr. Scott Sukenick J.D., Gen. Counsel & Corp. Sec. (Age 42)

What is SCYNEXIS's stock symbol?

SCYNEXIS trades on the NASDAQ under the ticker symbol "SCYX."

Who are SCYNEXIS's major shareholders?

SCYNEXIS's stock is owned by a number of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (19.37%), BlackRock Inc. (0.98%), Geode Capital Management LLC (0.65%), Connor Clark & Lunn Investment Management Ltd. (0.23%), Creative Planning (0.21%) and Bailard Inc. (0.05%). Company insiders that own SCYNEXIS stock include Gonzalez David Angulo and Marco Taglietti. View institutional ownership trends for SCYNEXIS.

Which institutional investors are selling SCYNEXIS stock?

SCYX stock was sold by a variety of institutional investors in the last quarter, including Bailard Inc., and Squarepoint Ops LLC. View insider buying and selling activity for SCYNEXIS.

Which institutional investors are buying SCYNEXIS stock?

SCYX stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, BlackRock Inc., Creative Planning, and HighMark Wealth Management LLC. Company insiders that have bought SCYNEXIS stock in the last two years include Gonzalez David Angulo, and Marco Taglietti. View insider buying and selling activity for SCYNEXIS.

How do I buy shares of SCYNEXIS?

Shares of SCYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SCYNEXIS's stock price today?

One share of SCYX stock can currently be purchased for approximately $0.77.

How big of a company is SCYNEXIS?

SCYNEXIS has a market capitalization of $76.35 million and generates $120,000.00 in revenue each year. The company earns $-53,710,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. SCYNEXIS employs 27 workers across the globe.

What is SCYNEXIS's official website?

The official website for SCYNEXIS is www.scynexis.com.

How can I contact SCYNEXIS?

SCYNEXIS's mailing address is 1 EVERTRUST PLAZA 13TH FLOOR, JERSEY CITY NJ, 07302. The company can be reached via phone at 201-884-5485 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.